Draper's tiny bio-MEM tech goes from a head-scratcher to a no-brainer

June 8, 2011 by Arezu Sarvestani

Draper Labs has watched micro-electro-mechanical technologies go from a head-scratcher to a no-brainer in the last 10 years, with possible commercial partnerships right around the corner.

Draper MEM

A bio-MEM drug delivery device developed by Draper Labs

Draper was into bio-MEMs before they were cool.

Micro-electro-mechanical systems, also known as MEMs, are tiny electrical machines that are common in consumer electronics and automotive sensors. Their presence in medical technology, however, is a much newer phenomenon.

In the last 10 years, as bio-MEMs technology has gone from being a head-scratcher to being a no-brainer, Jeffrey Borenstein has had a front-row seat.

"It definitely wasn't cool when we got started. It was definitely a curiosity at that time," said Borenstein, who is director of the Biomedical Engineering Center at Draper Laboratory. "Now they're saying, 'Of course.'"

Borenstein in the lab

Borenstein in the lab

The Cambridge, Mass.-based non-profit laboratory has been working on a slew of MEMs-driven medical technologies, including endoscopic imaging tools, sensing devices and drug delivery and organ assistance devices.

One of the most commercially viable works in progress are blood filtration pathways to replace the long tangle of tubing conventional artificial lung machines use to pump blood.

"With MEMs you can build these very smooth paths at the micron scale so that the blood flows much more smoothly. If it does that, then it's less likely to clot," Borenstein explained.

These devices aren't MEMs themselves, but MEM technologies are developed and stamped into bio-friendly materials to create the capillary-like paths.

Draper's pathways are biomimetic, meaning they are designed to match actual biological structures. MEMs etch tiny blood pathways with a precision that isn't possible with machine-shop tools, making the process of blood oxygenation safer and more efficient.

Comments

Features

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.